Details for Patent: 9,708,371
✉ Email this page to a colleague
Which drugs does patent 9,708,371 protect, and when does it expire?
Patent 9,708,371 protects LINZESS and is included in one NDA.
This patent has sixteen patent family members in ten countries.
Summary for Patent: 9,708,371
Title: | Treatments for gastrointestinal disorders |
Abstract: | The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. |
Inventor(s): | Kessler; Marco (Danvers, MA), Fretzen; Angelika (Somerville, MA), Zhao; Hong (Lexington, MA), Solinga; Robert (Brookline, MA), Volchenok; Vladimir (Waltham, MA) |
Assignee: | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 14/239,178 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,708,371 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 9,708,371
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. | ⤷ Try a Trial | |||
Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE | ⤷ Try a Trial | |||
Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-001 | Aug 30, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS. | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,708,371
PCT Information | |||
PCT Filed | August 17, 2012 | PCT Application Number: | PCT/US2012/051289 |
PCT Publication Date: | February 21, 2013 | PCT Publication Number: | WO2013/025969 |
International Family Members for US Patent 9,708,371
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2846230 | ⤷ Try a Trial | |||
China | 104053449 | ⤷ Try a Trial | |||
Denmark | 2776055 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |